Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARA | Q07869 | 9/20 | 0.54 |
| ▸ | ESR1 | P03372 | 4/20 | 0.47 |
| ▸ | ESR2 | Q92731 | 4/20 | 0.47 |
| ▸ | CA12 | O43570 | 2/20 | 0.47 |
| ▸ | CA1 | P00915 | 2/20 | 0.47 |
| ▸ | CA2 | P00918 | 2/20 | 0.47 |
| ▸ | CA7 | P43166 | 2/20 | 0.47 |
| ▸ | CA9 | Q16790 | 2/20 | 0.47 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.47 |
| ▸ | PPARG | P37231 | 7/20 | 0.47 |
| ▸ | PPARD | Q03181 | 3/20 | 0.47 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.45 |
| ▸ | BACE1 | P56817 | 1/20 | 0.45 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL977514 | 1.00 | PPARA (0.54) | PPARAESR1ESR2CA12CA1 | |
| SCHEMBL6419166 | 1.00 | PPARA (0.54) | PPARAESR1ESR2CA12CA1 | |
| SCHEMBL5379694 | 0.89 | ESR1 (0.45) | PPARAESR1ESR2CA12CA1 | |
| SCHEMBL5379702 | 0.89 | ESR1 (0.45) | PPARAESR1ESR2CA12CA1 | |
| SCHEMBL14501971 | 0.89 | PPARA (0.50) | PPARAESR1ESR2CA12CA1 | |
| SCHEMBL3535227 | 0.89 | ESR1 (0.58) | PPARAESR1ESR2PPARGPPARD | |
| SCHEMBL3535230 | 0.89 | ESR1 (0.58) | PPARAESR1ESR2PPARGPPARD | |
| SCHEMBL2554435 | 0.88 | PPARA (0.52) | PPARAPPARGPPARD | |
| SCHEMBL5360147 | 0.87 | ESR1 (0.51) | PPARAESR1ESR2CA12CA1 | |
| SCHEMBL3965096 | 0.87 | PPARA (0.50) | PPARAPPARGPPARD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 160 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1084101-B1 | NEW 3-ARYL-2-HYDROXYPROPIONIC ACID DERIVATIVE III | ASTRAZENECA AB (SE) | 2004-03-10 | — | — | EP | claimed |
| US-6660879-B2 | Use of the compound in clinical conditions associated with insulin resistance. | ASTRAZENECA AB (SE) | 2003-12-09 | — | — | US | claimed |
| US-12606533-B2 | 3-phenylpropylamine derivative | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2026-04-21 | — | — | US | disclosed |
| US-20250353824-A1 | 3-PHENYLPROPYLAMINE DERIVATIVE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2025-11-20 | — | — | US | disclosed |
| US-20220023262-A1 | COMPOSITION COMPRISING HIGH PURITY PYRROLE DERIVATIVE AND METHOD FOR PREPARATION THEREOF | ZYDUS LIFESCIENCES LIMITED (IN) | 2022-01-27 | — | — | US | disclosed |
| EP-3004053-B1 | A PROCESS FOR PREPARATION OF PYRROLES HAVING HYPOLIPIDEMIC HYPOCHOLESTEREMIC ACTIVITIES | CADILA HEALTHCARE LTD (IN) | 2021-03-24 | — | — | EP | disclosed |
| EP-3024816-B1 | PPAR-SPARING COMPOUNDS FOR THE TREATMENT OF METABOLIC DISEASES | METABOLIC SOLUTIONS DEV CO LLC (US) | 2020-06-03 | — | — | EP | disclosed |
| US-10435363-B2 | Process for preparation of pyrroles having hypolipidemic hypocholesteremic activities | CADILA HEALTHCARE LIMITED (IN) | 2019-10-08 | — | — | US | disclosed |
| US-10385017-B2 | Pyrrole compound, compositions and process for preparation thereof | CADILA HEALTHCARE LIMITED (IN) | 2019-08-20 | — | — | US | disclosed |
| US-9951009-B2 | Polymorphic form of pyrrole derivative and intermediate thereof | CADILA HEALTHCARE LIMITED (IN) | 2018-04-24 | — | — | US | disclosed |
| US-9951009-B2 | Polymorphic form of pyrrole derivative and intermediate thereof | CADILA HEALTHCARE LIMITED (IN) | 2018-04-24 | — | — | US | disclosed |
| EP-1084103-A1 | NEW 3-ARYL-2-HYDROXYPROPIONIC ACID DERIVATIVE (I) | AstraZeneca AB (SE) | 2001-03-21 | — | — | EP | disclosed |
| EP-1084101-A1 | NEW 3-ARYL-2-HYDROXYPROPIONIC ACID DERIVATIVE III | AstraZeneca AB (SE) | 2001-03-21 | — | — | EP | disclosed |
| EP-1084102-A1 | NEW 3-ARYL PROPIONIC ACID DERIVATIVES AND ANALOGS | AstraZeneca AB (SE) | 2001-03-21 | — | — | EP | disclosed |
| WO-2000063153-A1 | NEW COMPOUNDS, THEIR PREPARATION AND USE | NOVO NORDISK A/S (DK) | 2000-10-26 | — | — | WO | disclosed |
| WO-2000063189-A1 | CRYSTALLINE R- GUANIDINES, ARGININE OR (L) -ARGININE (2S) -2- ETHOXY -3-{4- [2-(10H -PHENOXAZIN -10-YL)ETHOXY]PHENYL}PROPANOATE | NOVO NORDISK A/S (DK) | 2000-10-26 | — | — | WO | disclosed |
| WO-2000023425-A1 | NEW COMPOUNDS, THEIR PREPARATION AND USE | NOVO NORDISK A/S (DK) | 2000-04-27 | — | — | WO | disclosed |
| WO-1999062870-A1 | NEW 3-ARYL-2-HYDROXYPROPIONIC ACID DERIVATIVE III | ASTRAZENECA AB (SE) | 1999-12-09 | — | — | WO | disclosed |
| WO-1999062872-A1 | NEW 3-ARYL-2-HYDROXYPROPIONIC ACID DERIVATIVE (I) | ASTRAZENECA AB (SE) | 1999-12-09 | — | — | WO | disclosed |
| WO-1999062871-A1 | NEW 3-ARYL PROPIONIC ACID DERIVATIVES AND ANALOGS | ASTRAZENECA AB (SE) | 1999-12-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250353824-A1 | 3-PHENYLPROPYLAMINE DERIVATIVE | SF1, SF3A1, SFXN1 | PPARA 3088/4885ESR1 1658/4885ESR2 581/4885 |
| US-12606533-B2 | 3-phenylpropylamine derivative | SF3A1, SF1, HTR1D | PPARA 3839/4885ESR1 1925/4885ESR2 161/4885 |
| US-10385017-B2 | Pyrrole compound, compositions and process for preparation thereof | GGPS1, TPMT, ADCYAP1R1 | PPARA 2446/4885ESR1 4438/4885ESR2 4487/4885 |
| US-10435363-B2 | Process for preparation of pyrroles having hypolipidemic hypocholesteremic activities | CYP51A1, LIPA, DHCR7 | PPARA 418/4885ESR1 4181/4885ESR2 4697/4885 |
| US-20220023262-A1 | COMPOSITION COMPRISING HIGH PURITY PYRROLE DERIVATIVE AND METHOD FOR PREPARATION THEREOF | DHPS, OGFOD1, OGDH | PPARA 1843/4885ESR1 4476/4885ESR2 4019/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.